FI115631B - Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus - Google Patents
Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus Download PDFInfo
- Publication number
- FI115631B FI115631B FI972775A FI972775A FI115631B FI 115631 B FI115631 B FI 115631B FI 972775 A FI972775 A FI 972775A FI 972775 A FI972775 A FI 972775A FI 115631 B FI115631 B FI 115631B
- Authority
- FI
- Finland
- Prior art keywords
- tetrahydro
- group
- quinuclidinyl
- isoquinolinecarboxylate
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
- C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
- C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32704594 | 1994-12-28 | ||
JP32704594 | 1994-12-28 | ||
PCT/JP1995/002713 WO1996020194A1 (fr) | 1994-12-28 | 1995-12-27 | Nouveaux derives de quinuclidine et composition pharmaceutique les contenant |
JP9502713 | 1995-12-27 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI972775A0 FI972775A0 (fi) | 1997-06-27 |
FI972775A FI972775A (fi) | 1997-08-22 |
FI115631B true FI115631B (fi) | 2005-06-15 |
Family
ID=18194699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI972775A FI115631B (fi) | 1994-12-28 | 1997-06-27 | Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus |
Country Status (24)
Country | Link |
---|---|
US (2) | US6017927A (fr) |
EP (1) | EP0801067B1 (fr) |
JP (1) | JP3014457B2 (fr) |
KR (1) | KR100386487B1 (fr) |
CN (1) | CN1045601C (fr) |
AT (1) | ATE233761T1 (fr) |
AU (1) | AU695616B2 (fr) |
CA (1) | CA2208839C (fr) |
DE (2) | DE122004000048I2 (fr) |
DK (1) | DK0801067T3 (fr) |
ES (1) | ES2193208T3 (fr) |
FI (1) | FI115631B (fr) |
FR (1) | FR04C0032I2 (fr) |
HU (1) | HU223778B1 (fr) |
LU (1) | LU91133I9 (fr) |
MX (1) | MX9704880A (fr) |
NL (1) | NL300141I2 (fr) |
NO (4) | NO2005012I1 (fr) |
NZ (1) | NZ298144A (fr) |
PL (1) | PL182344B1 (fr) |
PT (1) | PT801067E (fr) |
RU (1) | RU2143432C1 (fr) |
TW (1) | TW305842B (fr) |
WO (1) | WO1996020194A1 (fr) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008128028A2 (fr) * | 2007-04-11 | 2008-10-23 | Dr. Reddy's Laboratories Ltd. | Compositions à base de solifénacine |
US20100137358A1 (en) * | 1996-11-05 | 2010-06-03 | Dr. Reddy's Laboratories Ltd. | Solifenacin compositions |
FR2772378B1 (fr) * | 1997-12-12 | 2000-02-04 | Synthelabo | Derives d'imidazole, leur preparation et leur application en therapeutique |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
JP2001316670A (ja) * | 2000-05-02 | 2001-11-16 | Dainippon Ink & Chem Inc | 液晶組成物 |
US6916828B2 (en) * | 2000-06-27 | 2005-07-12 | Laboratorios S.A.L.V.A.T., S.A. | Carbamates derivatived from arylakylamines |
PL362989A1 (en) * | 2000-12-22 | 2004-11-15 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as m3 antagonists |
SK287414B6 (sk) | 2000-12-28 | 2010-09-07 | Laboratorios Almirall, S.A. | Chinuklidínové deriváty a kompozície s ich obsahom |
EP1405638B1 (fr) * | 2001-07-10 | 2011-02-09 | Astellas Pharma Inc. | Composition pharmaceutique comprenant de la quinuclidin-3'-yl 1-phenyl-1,2,3,4,-tetrahydroisoquinoline-2-carboxylate pour le traitement de la cystite interstitielle et/ou de la prostatite non-bactérienne |
HUP0500107A3 (en) * | 2001-12-20 | 2011-05-30 | Chiesi Farma Spa | 1-alkyl-1-azoniabicyclo[2.2.2.]octane carbamate derivatives, pharmaceutical compositions comprising thereof and their use as muscarinic receptor antagonists |
EP1552825A4 (fr) * | 2002-06-07 | 2009-11-25 | Astellas Pharma Inc | Agent therapeutique pour le traitement de l'hyperactivite vesicale |
ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
DE60230683D1 (de) | 2002-07-08 | 2009-02-12 | Ranbaxy Lab Ltd | 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat |
WO2004014853A1 (fr) | 2002-07-31 | 2004-02-19 | Ranbaxy Laboratories Limited | Derives 3,6-disubstitues d'azabicyclo [3.1.0]hexane utilises comme antagonistes des recepteurs muscariniques |
WO2004014363A1 (fr) | 2002-08-09 | 2004-02-19 | Ranbaxy Laboratories Limited | Derives d'azabicyclo[3.1.0] hexane 3,6-disubstitues, utiles en tant qu'agonistes de recepteurs muscariniques |
DE60231341D1 (de) | 2002-08-23 | 2009-04-09 | Ranbaxy Lab Ltd | Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten |
MXPA05003398A (es) * | 2002-10-29 | 2005-06-22 | Pharmacia & Upjohn Co Llc | Compuestos de amonio cuaternario. |
JP2006518707A (ja) | 2002-12-10 | 2006-08-17 | ランバクシー ラボラトリーズ リミテッド | ムスカリン様受容体アンタゴニストとしての3,6−二置換アザビシクロ[3.1.0]ヘキサン誘導体 |
PL376949A1 (pl) * | 2002-12-20 | 2006-01-09 | Dynogen Pharmaceuticals, Inc. | Sposoby leczenia niebolesnych zaburzeń pęcherza moczowego przy użyciu modulatorów podjednostki Ó2Ű kanału wapniowego |
EP1583741A1 (fr) | 2002-12-23 | 2005-10-12 | Ranbaxy Laboratories, Limited | Derives de 1-substitues-3-pyrrolidines comme antagonistes de recepteurs muscariniques |
AU2002347553A1 (en) | 2002-12-23 | 2004-07-14 | Ranbaxy Laboratories Limited | Flavaxate derivatives as muscarinic receptor antagonists |
US7488748B2 (en) | 2003-01-28 | 2009-02-10 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
CN1791399A (zh) * | 2003-03-21 | 2006-06-21 | 戴诺根医药品公司 | 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法 |
WO2004089898A1 (fr) | 2003-04-09 | 2004-10-21 | Ranbaxy Laboratories Limited | Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques |
US7560479B2 (en) | 2003-04-10 | 2009-07-14 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
EP1615634B1 (fr) | 2003-04-10 | 2007-05-16 | Ranbaxy Laboratories, Ltd. | Derives d'azabicyclo hexane en tant qu'antagonistes des recepteurs muscariniques |
BRPI0409302A (pt) | 2003-04-11 | 2006-04-11 | Ranbaxy Lab Ltd | derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos |
WO2004091597A2 (fr) * | 2003-04-15 | 2004-10-28 | Pharmacia & Upjohn Company Llc | Procede pour traiter le syndrome du colon irritable |
US20050175689A1 (en) * | 2003-10-27 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | Coated fine particles containing drug for intrabuccally fast disintegrating tablet |
EP1714965A4 (fr) * | 2004-02-09 | 2007-12-19 | Astellas Pharma Inc | Composition contenant du succinate de solifenacine |
WO2005077364A1 (fr) * | 2004-02-18 | 2005-08-25 | Yamanouchi Pharmaceutical Co., Ltd. | Préparation transdermique de solifénacine et procédé d'amélioration de la perméabilité transdermique de celle-ci |
WO2005087231A1 (fr) * | 2004-03-16 | 2005-09-22 | Astellas Pharma Inc. | Composition contenant de la solifenacine |
JPWO2005087231A1 (ja) * | 2004-03-16 | 2008-01-24 | アステラス製薬株式会社 | ソリフェナシン含有組成物 |
EP1728791A4 (fr) * | 2004-03-25 | 2008-12-10 | Astellas Pharma Inc | Composition pour la preparation pharmaceutique solide de solifenacine ou des sels de cette derniere |
ZA200608614B (en) * | 2004-03-25 | 2008-06-25 | Astellas Pharma Inc | Composition for solid pharmaceutical preparation of solifenacin or salt thereof |
WO2006035280A1 (fr) * | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Antagonistes des recepteurs muscariniques |
US20090105221A1 (en) * | 2004-09-29 | 2009-04-23 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
BRPI0519270A2 (pt) * | 2004-12-27 | 2009-01-06 | Astellas Pharma Inc | composiÇço farmacÊutica particulada estÁvel de solifenacina ou um sal |
WO2006070735A1 (fr) * | 2004-12-27 | 2006-07-06 | Astellas Pharma Inc. | Préparation pharmaceutique granulaire stable de solifénacine ou de son sel |
US20090131469A1 (en) * | 2005-02-25 | 2009-05-21 | Astellas Pharma Inc. | Pharmaceutical agent comprising solifenacin |
JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
WO2007007281A2 (fr) * | 2005-07-11 | 2007-01-18 | Ranbaxy Laboratories Limited | Antagonistes des recepteurs muscariniques |
US7815939B2 (en) | 2005-07-20 | 2010-10-19 | Astellas Pharma Inc. | Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms |
US20090221664A1 (en) | 2005-10-19 | 2009-09-03 | Abhijit Ray | Pharmaceutical compositions of muscarinic receptor antagonists |
CA2630846A1 (fr) * | 2005-12-21 | 2007-07-05 | Teva Pharmaceutical Industries Ltd. | Procedes de preparation de solifenacine |
CZ300699B6 (cs) | 2006-06-21 | 2009-07-22 | Zentiva, A. S. | Zpusob prípravy solifenacinu |
WO2008011462A2 (fr) * | 2006-07-19 | 2008-01-24 | Dr. Reddy's Laboratories Ltd. | Procédé de fabrication de solifénacine et de ses sels |
ES2298049B1 (es) | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
WO2008013851A2 (fr) * | 2006-07-24 | 2008-01-31 | Teva Pharmaceutical Industries Ltd. | Procédés de préparation de forme polymorphes de succinate de solifénacine |
WO2008019103A2 (fr) * | 2006-08-03 | 2008-02-14 | Teva Pharmaceutical Industries Ltd | Formes de solifénacine base et leur préparation |
TW200825084A (en) * | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
EP2102200A2 (fr) * | 2006-11-22 | 2009-09-23 | Medichem, S.A. | Procédé perfectionné pour la synthèse de solifénacine |
CZ300692B6 (cs) * | 2006-12-22 | 2009-07-15 | Zentiva, A. S. | Zpusob prípravy solifenacinu |
CN101711248A (zh) * | 2007-03-30 | 2010-05-19 | 医药化学公司 | 一种改进的素非那新合成工艺 |
US20090099365A1 (en) * | 2007-07-13 | 2009-04-16 | Nurit Perlman | Processes for solifenacin preparation |
EP2172201A4 (fr) * | 2007-07-20 | 2011-07-06 | Astellas Pharma Inc | Composition pharmaceutique pour une amélioration du symptôme des voies urinaires inférieures associé à une prostatomégalie |
EP2018850A1 (fr) * | 2007-07-24 | 2009-01-28 | Ratiopharm GmbH | Composition pharmaceutique comportant de la solifénacine ou sel acceptable pharmaceutiquement |
SI2216021T1 (sl) * | 2007-11-02 | 2013-01-31 | Astellas Pharma Inc. | Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja |
EP2484681A1 (fr) | 2007-12-04 | 2012-08-08 | Cadila Healthcare Limited | Sel de gentisate pur chimiquement et chiralement de solifénacine |
US8476297B2 (en) | 2007-12-04 | 2013-07-02 | Amgen Inc. | TRP-M8 receptor ligands and their use in treatments |
ITMI20080195A1 (it) | 2008-02-08 | 2009-08-09 | Dipharma Francis Srl | Procedimento per la preparazione di solifenacin |
EP2100599A1 (fr) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques |
EP2100598A1 (fr) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques |
US8404701B2 (en) | 2008-03-27 | 2013-03-26 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
PL385264A1 (pl) | 2008-05-23 | 2009-12-07 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny |
PL385265A1 (pl) | 2008-05-23 | 2009-12-07 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej |
EP2310387A2 (fr) | 2008-07-29 | 2011-04-20 | KRKA, D.D., Novo Mesto | Procede de preparation de sels de solifenacin et d' utilisation de ceux-ci aux compositions pharmaceutiques |
EP2181707A1 (fr) | 2008-11-04 | 2010-05-05 | Astellas Ireland Co., Ltd. | Utilisation combinée d'un antagoniste de récepteur alpha-adrénergique et d'un agent anti-muscarinique |
JP5553026B2 (ja) | 2009-02-04 | 2014-07-16 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
PL2406257T3 (pl) | 2009-03-09 | 2020-01-31 | Megafine Pharma (P) Ltd. | Nowy sposób wytwarzania solifenacyny i jej nowy produkt pośredni |
WO2010113840A1 (fr) | 2009-03-30 | 2010-10-07 | アステラス製薬株式会社 | Composition pharmaceutique solide contenant un corps amorphe de solifénacine |
WO2011048607A1 (fr) | 2009-09-25 | 2011-04-28 | Cadila Healthcare Limited | Procédés de préparation de solifénacine ou d'un de ses sels |
PL234208B1 (pl) | 2010-01-18 | 2020-01-31 | Zakl Farmaceutyczne Polpharma Spolka Akcyjna | Sposób wytwarzania bursztynianu solifenacyny |
ES2604705T3 (es) | 2010-03-31 | 2017-03-08 | Ono Pharmaceutical Co., Ltd. | Agente preventivo y/o remedio para el síndrome mano-pie |
US8748433B2 (en) | 2010-04-30 | 2014-06-10 | Merck Sharp & Dohme Corp. | β3 adrenergic receptor agonists |
CA2799942C (fr) | 2010-05-19 | 2018-07-17 | Astellas Pharma Inc. | Composition pharmaceutique contenant de la solifenacine |
US8772491B2 (en) | 2010-06-28 | 2014-07-08 | Aurobindo Pharma Ltd | Process for the preparation of solifenacin succinate |
EP2590973B1 (fr) | 2010-07-05 | 2016-08-31 | Crystal Pharma, S.A.U. | Sels de solifenacine |
CA2817336A1 (fr) | 2010-11-11 | 2012-05-18 | Hexal Ag | Succinate de solifenacine cristallin |
EP2510928A1 (fr) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires |
MX348723B (es) | 2011-05-10 | 2017-06-27 | Theravida Inc | Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva. |
US20140228575A1 (en) | 2011-06-22 | 2014-08-14 | Isochem | Process for the Preparation of Solifenacin and Salts Thereof |
KR101365849B1 (ko) | 2012-03-28 | 2014-02-24 | 경동제약 주식회사 | 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체 |
EP2867210A1 (fr) | 2012-07-02 | 2015-05-06 | Pharmathen S.A. | Procédé pour la préparation de solifénacine ou d'un de ses sels |
WO2014034860A1 (fr) | 2012-08-31 | 2014-03-06 | アステラス製薬株式会社 | Composition médicale administrée par voie orale |
EA038489B1 (ru) | 2012-09-05 | 2021-09-06 | Чейс Фамасьютикалз Корпорейшн | Антихолинэргическая нейропротективная композиция и способы |
CN103787969B (zh) | 2012-10-30 | 2016-07-06 | 上海京新生物医药有限公司 | 一种(1s)-1-苯基-3,4-二氢-2(1h)-异喹啉甲酸酯的制备方法 |
RU2661877C2 (ru) * | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
EP2778167A1 (fr) | 2013-03-11 | 2014-09-17 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Composition pharmaceutique comprenant solifenacin ou l'un de ses sels pharmaceutiquement acceptable |
WO2015007073A1 (fr) * | 2013-07-13 | 2015-01-22 | 北京市丰硕维康技术开发有限责任公司 | Composés à base de quinine, et isomères optiques, procédé de préparation et utilisation médicale associes |
US20170065589A1 (en) | 2014-05-06 | 2017-03-09 | Anthony G. Visco | Methods of treating or preventing preterm labor |
CN104592221A (zh) * | 2015-01-26 | 2015-05-06 | 中山奕安泰医药科技有限公司 | 一种合成索非那新的工艺 |
KR20160146428A (ko) | 2015-06-12 | 2016-12-21 | 한미정밀화학주식회사 | 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법 |
KR102148414B1 (ko) | 2017-05-15 | 2020-08-26 | 주식회사 서울제약 | 솔리페나신을 유효성분으로 하는 구강붕해필름 |
US20210163471A1 (en) | 2017-12-12 | 2021-06-03 | Arkuda Therapeutics | Progranulin modulators and methods of using the same |
MX2021014484A (es) * | 2019-06-12 | 2022-01-06 | Arkuda Therapeutics | Moduladores de la progranulina y metodos de uso de estos. |
CN113200979A (zh) * | 2021-04-13 | 2021-08-03 | 上海予君生物科技发展有限公司 | 一种琥珀酸索非那新的合成工艺 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0247266B1 (fr) * | 1986-01-07 | 1993-03-10 | Beecham Group Plc | Dérivés d'indole ayant une chaîne latérale azabicyclique, procédé pour leur préparation, produits intermédiaires et compositions pharmaceutiques |
IT1231238B (it) * | 1987-09-21 | 1991-11-26 | Angeli Inst Spa | Derivati ammidinici |
GB9023023D0 (en) * | 1990-10-23 | 1990-12-05 | Barlow Richard B | Pharmaceutical compositions |
GB9202443D0 (en) * | 1992-02-05 | 1992-03-18 | Fujisawa Pharmaceutical Co | A novel substituted-acetamide compound and a process for the preparation thereof |
JPH076635A (ja) * | 1993-06-18 | 1995-01-10 | Sony Corp | 信号伝送ケーブル |
AU7545894A (en) * | 1993-09-02 | 1995-03-22 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
JPH07258250A (ja) * | 1994-03-25 | 1995-10-09 | Yamanouchi Pharmaceut Co Ltd | エステル誘導体 |
ATE339121T1 (de) * | 2002-11-27 | 2006-10-15 | Selmac S R L | Vorrichtung zum positionieren und spannen geformter teile und damit ausgerüstete maschine |
-
1988
- 1988-09-19 NO NO2005012C patent/NO2005012I1/no unknown
-
1995
- 1995-12-27 NL NL300141C patent/NL300141I2/nl unknown
- 1995-12-27 TW TW084113934A patent/TW305842B/zh not_active IP Right Cessation
- 1995-12-27 PL PL95321019A patent/PL182344B1/pl unknown
- 1995-12-27 RU RU97112907/04A patent/RU2143432C1/ru active Protection Beyond IP Right Term
- 1995-12-27 KR KR1019970703649A patent/KR100386487B1/ko not_active IP Right Cessation
- 1995-12-27 DK DK95942276T patent/DK0801067T3/da active
- 1995-12-27 EP EP95942276A patent/EP0801067B1/fr not_active Expired - Lifetime
- 1995-12-27 MX MX9704880A patent/MX9704880A/es unknown
- 1995-12-27 DE DE200412000048 patent/DE122004000048I2/de active Active
- 1995-12-27 CN CN95197088A patent/CN1045601C/zh not_active Expired - Lifetime
- 1995-12-27 JP JP8520367A patent/JP3014457B2/ja not_active Expired - Lifetime
- 1995-12-27 US US08/860,377 patent/US6017927A/en not_active Expired - Lifetime
- 1995-12-27 WO PCT/JP1995/002713 patent/WO1996020194A1/fr active IP Right Grant
- 1995-12-27 HU HU9701895A patent/HU223778B1/hu active Protection Beyond IP Right Term
- 1995-12-27 AT AT95942276T patent/ATE233761T1/de active
- 1995-12-27 AU AU43553/96A patent/AU695616B2/en not_active Expired
- 1995-12-27 CA CA002208839A patent/CA2208839C/fr not_active Expired - Lifetime
- 1995-12-27 PT PT95942276T patent/PT801067E/pt unknown
- 1995-12-27 NZ NZ298144A patent/NZ298144A/en not_active IP Right Cessation
- 1995-12-27 DE DE69529844T patent/DE69529844T2/de not_active Expired - Lifetime
- 1995-12-27 ES ES95942276T patent/ES2193208T3/es not_active Expired - Lifetime
-
1997
- 1997-06-27 FI FI972775A patent/FI115631B/fi active Protection Beyond IP Right Term
- 1997-06-27 NO NO19973027A patent/NO318026B1/no not_active IP Right Cessation
-
1999
- 1999-05-14 US US09/312,392 patent/US6174896B1/en not_active Expired - Lifetime
-
2004
- 2004-12-30 FR FR04C0032C patent/FR04C0032I2/fr active Active
-
2005
- 2005-01-28 LU LU91133C patent/LU91133I9/fr unknown
- 2005-07-11 NO NO2005016C patent/NO2005016I2/no unknown
-
2017
- 2017-11-06 NO NO2017055C patent/NO2017055I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI115631B (fi) | Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus | |
Clark et al. | 2-(Quinuclidin-3-yl) pyrido [4, 3-b] indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists | |
AU2003226579B2 (en) | Azabicyclo derivatives as muscarinic receptor antagonists | |
JPH11502861A (ja) | サブスタンスpアンタゴニストとしての置換ベンゾラクタム化合物 | |
KR20100068290A (ko) | 알츠하이머병의 치료를 위한 알파 7 니코틴 아세틸콜린 수용체 리간드로서 퀴누클리딘-4-일메틸 1h-인돌-3-카르복실레이트 유도체 | |
WO1993016048A1 (fr) | Compose d'acetamide substitue | |
JP2002030084A (ja) | 1−アザビシクロアルカン化合物およびその医薬用途 | |
JP2674199B2 (ja) | 二環式アミン化合物およびその製造法 | |
RU2418794C2 (ru) | ПРОИЗВОДНЫЕ ИЗОХИНОЛИНА И БЕНЗО[h]ИЗОХИНОЛИНА, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА ГИСТАМИНА H3 | |
KR100241662B1 (ko) | 히드로이소퀴놀린 유도체 | |
WO1998051671A1 (fr) | Derives de tetrahydroisoquinoleine derives substitues servant de modulateurs de recepteurs de la dopamine d3 | |
CA1321996C (fr) | Diazepinones condenses, methodes de preparation et compositions pharmaceutiques a base de diazepinones | |
HUT54151A (en) | Process fopr producing new (r)-(-)-3-quinuclidinone derivatives and pharmaceutical compositions comprising such compounds | |
US20030158222A1 (en) | 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents) | |
US6358974B1 (en) | Isoquinoline derivatives | |
JPH0940646A (ja) | ベンゼン縮合環誘導体又はその塩 | |
JPH0240381A (ja) | 新規縮合ジアゼピノン類、それらの製造方法及びこれらの化合物を含有する医薬組成物 | |
CN101597260A (zh) | 新的毒蕈碱受体拮抗剂及其用途 | |
EP1086095B1 (fr) | Derives de tetrahydroisoquinoleine utilises comme modulateurs des recepteurs d 3 de la dopamine | |
JP2003081978A (ja) | スピロ環式化合物およびその医薬用途 | |
NO168586B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepinon-forbindelser | |
JP3007675B2 (ja) | 新規なインドール誘導体 | |
PAIN | United States Patent po | |
US20030191314A1 (en) | Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors | |
JP2015180608A (ja) | モルヒナン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 115631 Country of ref document: FI |
|
SPCF | Supplementary protection certificate application filed | ||
PC | Transfer of assignment of patent |
Owner name: ASTELLAS PHARMA INC. Free format text: ASTELLAS PHARMA INC. |
|
SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: 272 Extension date: 20181216 |
|
MA | Patent expired | ||
SPCE | Application for extension of a supplementary protection certificate [pediatric extension] |
Spc suppl protection certif: L20050024 |
|
SPCX | Supplementary protection certificate: correction |
Spc suppl protection certif: 272 Extension date: 20190622 |